Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects
Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects
复制标题
DOI：
10.1038/sj.bjc.6690713
复制
发表时间：
1999-10-01
影响因子：
8.8
通讯作者：
Cameron, IL
中科院分区：
文献类型：
--
作者：
Hardman, WE;Moyer, MP;Cameron, IL
拓扑异构酶I抑制剂CPT-11（伊立替康）的癌症化疗疗效通常受到严重迟发性腹泻诱导的限制。在动物研究中，CPT-11的使用与小肠和大肠粘膜的组织病理学损伤有关。本研究的结果表明，60 mg CPT-11/kg体重（i. v. q4 d x 6）可阻止喂食含7%玉米油饲料的小鼠中MCF 7人乳腺癌异种移植物的生长，但未导致显著消退。然而，当携带MCF 7的小鼠的饮食补充有3%或6%的鱼油时，相同的CPT-11治疗引起MGF 7异种移植物的显著消退。对接受CPT-11处理并喂食含有7%玉米油的饲料的小鼠的肠粘膜进行组织形态学分析表明，GPT-11处理诱导了肠粘膜的结构变化，这种变化在最后一次给予CPT-11后至少持续5天。用CPT-11处理并喂食含有鱼油的饮食的小鼠的肠粘膜结构与未接受CPT-11的小鼠组的结构相比基本上没有变化。这些发现表明，鱼油补充剂可能是CPT-11治疗的有用辅助剂。(C)1999年癌症研究运动。
The cancer chemotherapeutic efficacy elf the topoisomerase I inhibitor, CPT-11 (irinotecan) is often limited by the induction of severe delayed diarrhoea. In animal studies, CPT-11 use is associated with histopathological damage to the mucosa of the small and large intestines. Results from the present study demonstrate that 60 mg CPT-11 per kg body weight (i.v. q4d x 6) halted the growth, but did not cause significant regression, of MCF7 human breast carcinoma xenografts in mice fed a diet containing 7% corn oil. However, when the diet of the MCF7-bearing mice was supplemented with 3% or 6% fish oil, the same CPT-11 treatment caused significant regression of the MGF7 xenograft. Histomorphometric analyses of intestinal mucosa of mice treated with CPT-11 and fed the diet containing 7% corn oil indicated that treatment with GPT-11 induced structural changes in the intestinal mucosa which persisted at least 5 days after the last dose of CPT-11. The intestinal mucosal architecture of mice that were treated with CPT-11 and fed the diets containing fish oil was largely unchanged from the architecture of the group of mice which did not receive CPT-11. These findings indicate that fish oil supplements may be a useful adjunct to CPT-11 treatment. (C) 1999 Cancer Research Campaign.